CDM Projects

This study will replicate a FDA Sentinel study using the CNODES' adaptation of the Sentinel Common Data Model with Canadian data to determine whether there is an increased risk of intentional self-harm among adult patients with diabetes who are newly treated with GLP-1 receptor agonists compared to those who are newly treated with SGLT-2 inhibitors or DPP-4 inhibitors.

This pilot project aims to conduct a cohort study in 4 Canadian provinces to demonstrate the feasibility of replicating a US FDA Sentinel TreeScan signal-detection analysis using Ozempic as the case study.

The objective of this pilot project is to determine the utilization of antidiabetic drugs among pregnant people living in Canada using CNODES' adaptation of the Sentinel Common Data Model.

The risk of arterial thromboembolism and venous thromboembolism among patients diagnosed with COVID-19 varied by country. This variation was observed among patients initially diagnosed in the ambulatory setting and the hospital setting, and before and during COVID-19 vaccine availability. Differences in healthcare systems, data sources, prevalence of underlying comorbid conditions, and approaches to COVID-19 and thromboembolism case definition may have contributed to the variation in thromboembolism risk estimates observed between countries.

In Canada, an immediate steep decline in valsartan use was observed after the July 2018 recall accompanied by increased switching to other angiotensin receptor blocker (ARB) products. Subsequent recalls for losartan and irbesartan were also associated with increased switching, but overall trends in use remained unchanged. Despite availability of uncontaminated ARB products at the time of the recall, findings show that the immediate response was to switch patients to another ARB.

This population-based study of COVID-19 outpatients in three Canadian provinces, demonstrated that use of systemic corticosteroid therapy as a treatment for COVID-19 was limited during the first year of the pandemic.